Literature DB >> 25128532

Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.

Paul Y Kim1, Trang T Vu2, Beverly A Leslie1, Alan R Stafford1, James C Fredenburgh1, Jeffrey I Weitz3.   

Abstract

Fibrin (Fn) clots formed from γ'-fibrinogen (γ'-Fg), a variant with an elongated γ-chain, are resistant to lysis when compared with clots formed from the predominant γA-Fg, a finding previously attributed to differences in clot structure due to delayed thrombin-mediated fibrinopeptide (FP) B release or impaired cross-linking by factor XIIIa. We investigated whether slower lysis of γ'-Fn reflects delayed plasminogen (Pg) binding and/or activation by tissue plasminogen activator (tPA), reduced plasmin-mediated proteolysis of γ'-Fn, and/or altered cross-linking. Clots formed from γ'-Fg lysed more slowly than those formed from γA-Fg when lysis was initiated with tPA/Pg when FPA and FPB were both released, but not when lysis was initiated with plasmin, or when only FPA was released. Pg bound to γ'-Fn with an association rate constant 22% lower than that to γA-Fn, and the lag time for initiation of Pg activation by tPA was longer with γ'-Fn than with γA-Fn. Once initiated, however, Pg activation kinetics were similar. Factor XIIIa had similar effects on clots formed from both Fg isoforms. Therefore, slower lysis of γ'-Fn clots reflects delayed FPB release, which results in delayed binding and activation of Pg. When clots were formed from Fg mixtures containing more than 20% γ'-Fg, the upper limit of the normal level, the delay in lysis was magnified. These data suggest that circulating levels of γ'-Fg modulate the susceptibility of clots to lysis by slowing Pg activation by tPA and provide another example of the intimate connections between coagulation and fibrinolysis.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Enzyme Kinetics; Fibrinogen; Fibrinolysis; Plasminogen; Tissue Plasminogen Activator (tPA); γ′-Fibrinogen

Mesh:

Substances:

Year:  2014        PMID: 25128532      PMCID: PMC4183790          DOI: 10.1074/jbc.M114.588640

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains.

Authors:  G Tsurupa; L Medved
Journal:  Biochemistry       Date:  2001-01-23       Impact factor: 3.162

2.  Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate.

Authors:  J P Collet; C Nagaswami; D H Farrell; G Montalescot; J W Weisel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-12-01       Impact factor: 8.311

3.  A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.

Authors:  Mark Schneider; Michael Nesheim
Journal:  J Biol Chem       Date:  2004-01-08       Impact factor: 5.157

4.  Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin.

Authors:  Caroline H Pospisil; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

5.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

Review 6.  Human plasminogen.

Authors:  F J Castellino; J R Powell
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure.

Authors:  Amy V Cooper; Kristina F Standeven; Robert A S Ariëns
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

8.  The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation.

Authors:  E Suenson; P Bjerrum; A Holm; B Lind; M Meldal; J Selmer; L C Petersen
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

9.  Association of gammaA/gamma' fibrinogen levels and coronary artery disease.

Authors:  Rehana S Lovely; Lisa A Falls; Hamid A Al-Mondhiry; Charles E Chambers; Gary J Sexton; Hanyu Ni; David H Farrell
Journal:  Thromb Haemost       Date:  2002-07       Impact factor: 5.249

10.  The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis.

Authors:  E L Hethershaw; A L Cilia La Corte; C Duval; M Ali; P J Grant; R A S Ariëns; H Philippou
Journal:  J Thromb Haemost       Date:  2014-02       Impact factor: 5.824

View more
  5 in total

1.  High fibrinogen γ' levels in patient plasma increase clot formation at arterial and venous shear.

Authors:  Fraser L Macrae; Frauke Swieringa; Johan W M Heemskerk; Robert A S Ariëns
Journal:  Blood Adv       Date:  2021-09-14

2.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.

Authors:  Ran Ni; Miguel A D Neves; Chengliang Wu; Samantha E Cerroni; Matthew J Flick; Heyu Ni; Jeffrey I Weitz; Peter L Gross; Paul Y Kim
Journal:  J Thromb Haemost       Date:  2020-09       Impact factor: 5.824

3.  Mathematical modeling to understand the role of bivalent thrombin-fibrin binding during polymerization.

Authors:  Michael A Kelley; Karin Leiderman
Journal:  PLoS Comput Biol       Date:  2022-09-15       Impact factor: 4.779

4.  Fibrin γ/γ' influences the secretion of fibrinolytic components and clot structure.

Authors:  Miriam Cantero; Héctor Rojas; Eduardo Anglés-Cano; Rita Marchi
Journal:  BMC Mol Cell Biol       Date:  2019-11-01

Review 5.  Recent advances in understanding, diagnosing and treating venous thrombosis.

Authors:  Noel C Chan; Jeffrey I Weitz
Journal:  F1000Res       Date:  2020-10-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.